Insulet is a medical technology company focused on the development, manufacturing, and marketing of an insulin infusion system for people with insulin-dependent diabetes. The company exceeded earnings estimates for Q1, driven by the strong demand for its portable insulin pumps. The customer base already includes over 500,000 active users with...
The Best Growth Stocks by Revenue & Profit
Stocks with high revenue and earnings growth on a TTM basis, ranked by distance from the 52-week high.
| Rank | Stock | Price | Rev. Gr. | Dist. 52WH | Perf. 20D |
|---|---|---|---|---|---|
| WKN | Symbol | EPS Growth | Rel. Strength | |||
| 1 | Verisk Analytics | 278.09 $ | 26.37 % | 9.32 % | -3.45 % |
| A0YA2M | VRSK | 88.86 % | 86 | |||
| 2 | Palomar Holdings | 130.13 $ | 40.22 % | 9.49 % | -0.24 % |
| A2PHB6 | PLMR | 49.48 % | 96 | |||
| 3 | HCI Group | 137.14 $ | 49.16 % | 9.70 % | -1.56 % |
| A1W02H | HCI | 199.39 % | 85 | |||
| 4 | Progressive | 259.68 $ | 22.67 % | 11.37 % | -6.44 % |
| 865496 | PGR | 198.70 % | 88 | |||
| 5 | Universal Technical Institute | 26.47 $ | 20.63 % | 13.39 % | -1.64 % |
| 590097 | UTI | 533.33 % | 96 | |||
| 6 | Halozyme Therapeutics | 56.53 $ | 21.35 % | 14.34 % | -7.15 % |
| A0DLHS | HALO | 60.73 % | 92 | |||
| 7 | Insulet | 246.49 $ | 27.42 % | 14.84 % | -0.76 % |
| A0MQX8 | PODD | 250.00 % | 92 | |||
| 8 | Interdigital | 192.19 $ | 28.53 % | 17.15 % | -9.55 % |
| A0MWY3 | IDCC | 41.33 % | 98 | |||
| 9 | Tradeweb Markets | 122.34 $ | 29.44 % | 19.86 % | -8.22 % |
| TW | 20.69 % | 84 | |||
| 10 | Catalyst Pharmaceuticals | 20.86 $ | 32.17 % | 20.27 % | -1.62 % |
| A0LCUL | CPRX | 111.86 % | 90 | |||
Subscribe now to see the full ranking
Already a subscriber? Login
Sample Issue
$
0
one issue
Bestseller
Trial Subscription
$
33
1 month
Insulet (PODD) is regarded as the world's leading provider of tubeless insulin pumps and sees itself as the market leader in automated insulin delivery. Since April 28, Ashley McEvoy has taken over as CEO, bringing extensive experience from her previous leadership role in Johnson & Johnson's medical technology division. She emphasizes: "We are already...